CVS Health (NYSE:CVS) announces
that CVS Caremark, its pharmacy benefit manager, is now offering
diabetic members a new solution, RxZERO, that enables employers and
health plan sponsors to leverage formulary and plan design approaches to
offer all categories of diabetes medications, including meds for type 2
diabetes, with no co-pays for their members without raising costs for
the plan sponsor or increasing premiums or deductibles for all plan
members.
CVS Caremark says the average out-of-pocket cost per year for diabetes drugs for members is $467.24.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.